Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) EBT (2024 - 2026)

Kura Oncology has reported EBT over the past 3 years, most recently at -$73.3 million for Q1 2026.

  • Quarterly EBT fell 28.18% to -$73.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$16.1 million through Mar 2026, up 91.03% year-over-year, with the annual reading at -$172.0 million for FY2024, N/A changed from the prior year.
  • EBT was -$73.3 million for Q1 2026 at Kura Oncology, down from $197.4 million in the prior quarter.
  • Over five years, EBT peaked at $197.4 million in Q4 2025 and troughed at -$74.1 million in Q3 2025.
  • The 3-year median for EBT is -$54.4 million (2024), against an average of -$27.3 million.
  • The largest YoY upside for EBT was 1247.98% in 2025 against a maximum downside of 36.23% in 2025.
  • A 3-year view of EBT shows it stood at -$17.2 million in 2024, then skyrocketed by 1247.98% to $197.4 million in 2025, then tumbled by 137.14% to -$73.3 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's EBT are -$73.3 million (Q1 2026), $197.4 million (Q4 2025), and -$74.1 million (Q3 2025).